Recent Advances in Systemic Chemotherapy for Metastatic Colorectal Cancer

Yuji Miyamoto, Eiji Oki, Hiroshi Saeki, Yoshihiko Maehara, Hideo Baba

Research output: Contribution to journalReview articlepeer-review

2 Citations (Scopus)


The recent development of chemotherapeutic agents and biomarkers have remarkably improved treatment outcomes of metastatic colorectal cancer (mCRC). However, decision making regarding the choice of therapy for mCRC has been complicated by the availability of many different treatment options. In this review, we will discuss the clinical evidence for current systemic treatment, including the key roles of 3 cytotoxic drugs and oral fluoropyrimidines, the appropriate use of anti-VEGF and anti-EGFR therapy, the significance of RAS mutation status as a predictive marker for anti-EGFR therapy, and new agents for salvage therapy (regorafenib and TAS-102 [TFTD]).

Original languageEnglish
Pages (from-to)15-23
Number of pages9
JournalGan to kagaku ryoho. Cancer & chemotherapy
Issue number1
Publication statusPublished - Jan 1 2016

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research


Dive into the research topics of 'Recent Advances in Systemic Chemotherapy for Metastatic Colorectal Cancer'. Together they form a unique fingerprint.

Cite this